Chongqing Peg-Bio Biopharm Co., Ltd.
Categories
-
Country/Region:China
-
On CPHI since:2023
Products from Chongqing Peg-Bio Biopharm Co., Ltd. (1)
-
Product Semaglutide Intermediate (Recombinant)
Semaglutide is a new 2nd Generation GLP-1RA drug developed by Novo Nordisk. In Dec. 2019, Semaglutide injection (brand name: Ozempic, 4mg/3ml) was approved by FDA to improve glycemic control in adults with type 2 diabetes. In Jun. 2021, Semaglutide injection (brand name: Wegovy, 2.4mg/dose) was approved by...